Optibiotix Health Share Discussion Threads

[nobbygnome] 30/5/2018 07:10

Well I was one of them which is why I made the post last night. However, I don't really know who my fellow placees are. I actually bought some at 65p at the end of last week so of course I saw 62p as a good price!

I am sure there will be some wringing of hands about the fund raising today but of course ultimately it is a good development. Minimal dilution and now they have more money to develop some of the areas more quickly and thoroughly!

Nobby

[rollthedice] 30/5/2018 07:10

Totally predicable placing based on cash position disclosed in final results. It's a small placing at a modest discount which is to be used to accelerate opportunities.

[michaelmouse] 30/5/2018 07:08

GAME SET AND MATCH.

I GUESSED THAT'S WHY THE TROLLS HAD TOTALLY DISAPPEARED INTO OBLIVION AND THE PAID PUMP MERCHANTS HAD BEEN QUIET IN RECENT WEEKS.

LOL.

[2350220] 30/5/2018 07:07

Not the sort of RNS we were hoping for IMHO.
John

[aspex] 30/5/2018 07:04

Really quite a small placing which should not upset existing holders. Who to is the questions?

[nobbygnome] 29/5/2018 19:06

Actually I doubt it, the forecast is not too good 😜....

[zebbo] 29/5/2018 17:20

I think we will have sunshine tomorrow morning...;-)

[nobbygnome] 29/5/2018 17:10

I think we will have an RNS tomorrow morning.....

[suzypink] 29/5/2018 13:35

Good old predictive . ..... a clean brexit !!!@

[suzypink] 29/5/2018 13:33

Just following the market today because so many obstacles are being put in the way of a clean credit . ..

[bobalot] 29/5/2018 07:47

NEWS FROM SKINBIO:

RNS Non-Regulatory

TIDMSBTX

SkinBioTherapeutics PLC

29 May 2018

SkinBioTherapeutics plc

SkinBioTherapeutics to fulfil industrial partner role in skin health research grant awarded to the University of Manchester

Manchester, UK - 29 May 2018 - SkinBioTherapeutics plc (AIM: SBTX, the 'Company'), a life science company focused on skin health, announces its collaboration as industrial partner in a grant awarded by the Biotechnology and Biological Sciences Research Council (BBSRC) to The University of Manchester (the 'University').

The grant of approximately GBP600k provides the University with non-dilutive funding for up to three years to investigate how ageing affects the skin and in particular, its microbiome. In the gut, it is currently understood that certain fibres can promote the growth of beneficial bacteria (called a 'prebiotic effect') but research is needed to determine how this principle applies to skin health and which molecules could be prebiotic for the skins microbiome.

BBSRC awarded the grant to enable the University to carry out research which could lead to the development of novel ways to improve the health of the skin microbiome during ageing and in turn, support new approaches to prevent age-related skin conditions and promote long-term skin health. Grant applications of this nature are extremely competitive and the award is a strong external validation of the capabilities of both the University and SkinBioTherapeutics.

SkinBioTherapeutics is supporting the programme as the industrial partner to further work in this exciting new area of the skin microbiome. As industrial partner, SkinBioTherapeutics has first refusal on any IP generated by the project. The Company will be well placed to develop any relevant findings with the potential to extend its current portfolio of indications in skin health, anti-infection and repair.

Dr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:

"We have a long-standing relationship with the University, and I am delighted this will continue through this latest collaboration. It is testament to both teams that we have been successful with such a prestigious award.

"Unlike the gut, virtually nothing is known about possible prebiotics for skin. This study will provide the foundations for developing novel prebiotic treatments for aged skin. This work is very complementary to the work that we have already underway at SkinBioTherapeutics in skin care, anti-infection and repair."

-Ends-

[anderson3] 28/5/2018 21:26

hxxp://akums.in

[2350220] 28/5/2018 21:22

Ta paulhoodwinked,
John

[paulhoodwinked] 28/5/2018 20:04

Of course it's real. elrico mentioned something about OPTI and government officials wooing Indian businesses before he went awol. He is on the money yet again. We really could do with him back here.

[2350220] 28/5/2018 19:51

IS this for real?
If so, that's great, but I don't understand why the DTI would be tweeting about a deal which a tiny AIM company has done.

Let's hope that we have a better week this week.

John

[paulhoodwinked] 28/5/2018 17:13

Great find Parob. Now we have the DTI ramping Opti. Excuse me, i have doctored the address so it works.

[parob] 28/5/2018 17:00

Look who's been tweeting about OPTI:https://mobile.twitter.com/tradegovukIND/status/1001088102566248453

[slartybartfaster] 28/5/2018 08:55

Seed test site.

[slartybartfaster] 27/5/2018 12:23

TT it was rns, referred to 3 different formulations split 3x10k. They had the product at Uki.

[trotterstrading] 27/5/2018 12:21

Ignore me.. I was reading the wrong RNS!

[trotterstrading] 27/5/2018 12:19

DC, where did you get the 30k box Pharmabiota Order info? I've not found anything on the order size?

[aspex] 26/5/2018 19:52

Pharmabiota appear to have an emphasis on the Australian market for their products so the result is not surprising.

[dire cons] 26/5/2018 11:33

That New Zealand order was 30k boxes. If they were white-boxed at guess between 5 and 10 quid a box, that's quite a substantial first order from a relatively small player.
Any thoughts?